Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

Fig. 3

Immunohistochemical analysis of FABP4 and CD36 expression with regards to SARIFA-status. A No SARIFA-dependent differences regarding FABP4 expression could be observed (IF: p = 0.53, TC: p = 0.89). D CD36 immunohistochemistry revealed CD36 upregulation, specifically at the invasion front (IF: p = 0.0012, TC: p = 0.4). B, E Exemplary images of SARIFA-positive cases. C, F Exemplary images of SARIFA-negative cases, scale bars: 100 µm. SARIFA: Stroma-AReactive-Invasion-Front-Areas FABP4: fatty-acid binding protein 4, CD36: cluster of differentiation 36, fatty-acid translocase, IF: invasion front, TC: tumor center

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us